| Expression pattern: |
UN |
| Associated gene: |
CUGBP Elav-like family member 1 (CELF1), FUS RNA-binding protein (FUS), Muscleblind-like splicing regulator 1 (MBNL1), Sterile alpha motif domain-containing 4A (SAMD4A), Serine and arginine-rich splicing factor 1 (SRSF1), Serine and arginine-rich splicing factor 2 (SRSF2), Serine and arginine-rich splicing factor 3 (SRSF3), Serine and arginine-rich splicing factor 5 (SRSF5), Polypyrimidine tract binding protein 1 (PTBP1), Heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) |
| Associated microRNA: |
miR-4767, miR-4763-5p, miR-6729-3p, miR-4649-5p, miR-6849-3p |
| Biological function: |
Inversely associated with TNM stage (lower expression more frequent in TNM III vs TNM II); predicted to sponge miRNAs and bind RBPs; predicted to contain an ORF (potential translation). |
| Molecular mechanism: |
Predicted miRNA sponging and predicted binding to RNA-binding proteins; predicted ORF without predicted IRES. |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; divergent primers PCR; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circ-BCL2L12-2 expression is inversely associated with TNM stage in colorectal cancer. |
| Description: |
circ-BCL2L12-2 is a newly identified BCL2L12-derived circRNA in colorectal cancer. Its expression is inversely associated with TNM stage, and it is predicted to interact with multiple miRNAs/RBPs and to contain an ORF (potential translation), though its prognostic value was not supported in this cohort. |
| Confidence score: |
0.5841 |